gefitinib has been researched along with xav939 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (xav939) | Trials (xav939) | Recent Studies (post-2010) (xav939) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 186 | 0 | 179 |
| Protein | Taxonomy | gefitinib (IC50) | xav939 (IC50) |
|---|---|---|---|
| Chain A, Tankyrase-1 | Homo sapiens (human) | 0.011 | |
| Chain A, Tankyrase-1 | Homo sapiens (human) | 0.011 | |
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 0.0656 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.9968 | |
| Protein Wnt-3a | Mus musculus (house mouse) | 0.078 | |
| Protein Wnt-3a | Homo sapiens (human) | 0.078 | |
| Protein mono-ADP-ribosyltransferase PARP14 | Homo sapiens (human) | 5.8942 | |
| Vesicular acetylcholine transporter | Rattus norvegicus (Norway rat) | 0.015 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 0.052 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.0792 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 4.3776 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.8354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Fang, D; Li, HY; Liang, C; Liu, FY; Niu, J; Sun, H; Wang, X; Xie, SQ; Zhang, YD | 1 |
2 other study(ies) available for gefitinib and xav939
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Suppression of epidermal growth factor receptor-mediated β-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Phosphoinositide-3 Kinase Inhibitors | 2019 |